Drug intelligence / Profile preview

HL-028

Development stage: Preclinical
Lead developer: Shanghai KeChow Pharmaceuticals
Modality: Small Molecules

Overview

HL-028 is an investigational small molecule targeted therapy currently in the preclinical and research stage of development by Kechow Pharma (also known as Kechu). It is being developed for the treatment of solid tumors. As of early 2024, the specific molecular target and mechanism of action for HL-028 have not been publicly disclosed by the developer. The drug is part of Kechow Pharma's oncology pipeline, which focuses on the discovery and development of precision medicines for cancer treatment.

Beyond the preview

Go deeper on HL-028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL-028.

Explore the full profile